Compare iShares MSCI India ETF (INDA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI India ETF trades at $47.7 (market cap $5.71B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: iShares MSCI India ETF is far larger — about 5.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 60 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| INDA | MRVI | |
|---|---|---|
Market Cap | $5.71B | $972.90M |
Volume | 3,011,243 | 4,325,710 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $9.00 |
52-Week Low | $45.42 | $2.83 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $47.24, up 1.99% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and pharmaceutical sector export issues. Recent news highlights India's energy security concerns and IT sector weakness, creating a cautious market environment despite the country's economic growth narrative.
The outlook remains cautious with technical weakness outweighing short-term gains. Investment opportunity exists for long-term exposure to India's growth story, but risks include energy sector instability, weather-dependent agricultural output, and global trade tensions affecting key export industries.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
